PE Biosystems DNA Analyzer Demand, Strong Sales Boost Stock 26% In Q3
This article was originally published in The Gray Sheet
Continued strong demand for the ABI Prism 3700 DNA analyzer, order growth across a broad range of additional products and release of financial results ahead of some analysts' estimates contributed to a 25.9% jump in PE Biosystems' stock price during the third quarter.
You may also be interested in...
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
GE Medical Systems will gain a controlling stake of the U.S. mobile C-arm fluoroscopy imaging market through its $480 mil. purchase of OEC Medical Systems, announced Aug. 9.
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.